Sphere Fluidics, a company developing single-cell analysis systems underpinned by its patented picodroplet technology, has appointed Richard Hammond as Chief Technical Officer.
In his role as Chief Technical Officer, Richard will be responsible for driving innovation and growing Sphere Fluidics’ product range, including productising several patented prototypes currently in development. Following expansion of the senior team in May 2021, the appointment demonstrates the company’s ongoing strategic plans to expand its portfolio of single-cell analysis and monoclonality assurance systems to facilitate accelerated biotherapeutic discovery and development.
Richard Hammond, MA MEng, joins Sphere Fluidics with over 20 years’ experience in managing the development of commercial products for healthcare and life sciences. Richard has held numerous senior positions, including leading product and technology development at Alere, Cambridge Consultants and DNA Electronics. With extensive technical expertise, he has worked in cutting-edge research areas, such as automated cell transfection, CAR-T cell therapy manufacture and digital data storage in DNA. Richard holds MA and MEng degrees in engineering from King’s College, University of Cambridge.
Richard Hammond, CTO, Sphere Fluidics, commented: “Sphere Fluidics has an excellent reputation for providing world-class products for single cell analysis, and I’m delighted to take the opportunity to build on this further. There is extensive scope for expansion into new, emerging application areas and international markets, and I look forward to working closely with the team to take advantage of this, especially with our outstanding new facilties.”
For more information about Sphere Fluidics, please visit: spherefluidics.com.